Jonathan Sorof, M.D.

Jonathan Sorof, M.D.

Senior Vice President, Head of Medical Affairs and Program Team Lead, Oxbryta®

Dr. Sorof joined GBT in July 2017 as senior vice president, medical and regulatory affairs, and was appointed senior vice president, head of medical affairs, and program team leader, Oxbryta®, in October 2019. He spent nine years in academic clinical practice at the Texas Medical Center in Houston conducting NIH-funded clinical research. Prior to joining GBT, Dr. Sorof spent 15 years at AstraZeneca and Genentech/Roche, where he held U.S. and global positions of increasing responsibility, including U.S. therapeutic area head for cardiovascular and metabolic diseases, global head of pediatric oncology regulatory affairs, and most recently as global therapeutic area head for immunology, respiratory and ophthalmology based in Basel, Switzerland. While at AstraZeneca and Genentech, Dr. Sorof leveraged his pediatric experience in the design, execution and completion of multiple pediatric clinical trials, resulting in successful negotiations with the FDA for updated pediatric labeling for several marketed products and for innovative clinical development strategies for pediatric rare diseases. He has led preparations for 10 product launches in primary care, specialty care and rare diseases in the United States and other countries in a variety of therapeutic areas. Dr. Sorof received an M.D. from the University of Pennsylvania School of Medicine and trained in pediatrics at Children’s National Medical Center in Washington D.C., and in pediatric nephrology at the University of California San Francisco (UCSF).